_id
690f3844ccc777a4e85d184c
Ticker
BRIBF
Name
Brii Biosciences Limited
Exchange
PINK
Address
Building 7, International Science Park, Beijing, China, 100192
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.briibio.com
Description
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Last Close
0.2459
Volume
4154
Current Price
0.1882
Change
0
Last Updated
2026-01-20T16:57:27.050Z
Image
-
Ipo Date
-
Market Cap
135650144
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-06-30
Revenue
496500
Cost Of Revenue
-
Gross Profit
496500
Operating Expenses
87622500
Operating Income
-87126000
Interest Expense
-
Pretax Income
-74424000
Net Income
-74033500
Eps
-0.10231952921144576
Dividends Per Share
-
Shares Outstanding
720776548
Income Tax Expense
-
EBITDA
-86564750
Operating Margin
-17548.036253776438
Total Other Income Expense Net
12702000
Cash
1507500000
Short Term Investments
567235000
Receivables
-
Inventories
-
Total Current Assets
2089168000
Property Plant Equipment
11252000
Total Assets
2485281000
Payables
-
Short Term Debt
4523000
Long Term Debt
0
Total Liabilities
51475000
Equity
2485464000
Bs_currency_symbol
CNY
Depreciation
561250
Change In Working Capital
-
Cash From Operations
-
Capital Expenditures
0
Cash From Investing
-
Cash From Financing
-
Net Change In Cash
-
Cf_currency_symbol
-
PE
-
PB
0.05478755129826866
ROE
-2.9786591155615207
ROA
-2.9788784447311993
FCF
-
Fcf Percent
-
Piotroski FScore
0
Health Score
41
Deep Value Investing Score
6.5
Defensive Investing Score
5
Dividend Investing Score
1.5
Economic Moat Investing Score
4.8
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
3.5
Net Net Investing Score
6.5
Quality Investing Score
2.5
Value Investing Score
6.5
Quarters > 0 > quarter
2025-06-30
Quarters > 0 > income Statement > revenue
496500
Quarters > 0 > income Statement > cost Of Revenue
-
Quarters > 0 > income Statement > gross Profit
496500
Quarters > 0 > income Statement > operating Expenses
87622500
Quarters > 0 > income Statement > operating Income
-87126000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-74424000
Quarters > 0 > income Statement > net Income
-74033500
Quarters > 0 > income Statement > eps
-0.10231952921144576
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
723552000
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-86564750
Quarters > 0 > income Statement > operating Margin
-17548.036253776438
Quarters > 0 > income Statement > total Other Income Expense Net
12702000
Quarters > 0 > income Statement > currency_symbol
-
Quarters > 0 > balance Sheet > cash
1507500000
Quarters > 0 > balance Sheet > short Term Investments
567235000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
2089168000
Quarters > 0 > balance Sheet > property Plant Equipment
11252000
Quarters > 0 > balance Sheet > total Assets
2485281000
Quarters > 0 > balance Sheet > payables
-
Quarters > 0 > balance Sheet > short Term Debt
4523000
Quarters > 0 > balance Sheet > long Term Debt
0
Quarters > 0 > balance Sheet > total Liabilities
51475000
Quarters > 0 > balance Sheet > equity
2485464000
Quarters > 0 > balance Sheet > currency_symbol
CNY
Quarters > 0 > cash Flow > net Income
-74033500
Quarters > 0 > cash Flow > depreciation
561250
Quarters > 0 > cash Flow > change In Working Capital
-
Quarters > 0 > cash Flow > cash From Operations
-
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-
Quarters > 0 > cash Flow > cash From Financing
-
Quarters > 0 > cash Flow > net Change In Cash
-
Quarters > 0 > cash Flow > currency_symbol
-
Quarters > 0 > ratios > PE
-0.10231952921144576
Quarters > 0 > ratios > PB
0.05478755129826866
Quarters > 0 > ratios > ROE
-2.9786591155615207
Quarters > 0 > ratios > ROA
-2.9788784447311993
Quarters > 0 > ratios > FCF
-
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
41
Quarters > 1 > quarter
2024-12-31
Quarters > 1 > income Statement > revenue
13890500
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
13890500
Quarters > 1 > income Statement > operating Expenses
108018000
Quarters > 1 > income Statement > operating Income
-94127500
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-114571500
Quarters > 1 > income Statement > net Income
-113813500
Quarters > 1 > income Statement > eps
-0.15574270743959528
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
730779000
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-93566250
Quarters > 1 > income Statement > operating Margin
-677.6393938303156
Quarters > 1 > income Statement > total Other Income Expense Net
-20444000
Quarters > 1 > income Statement > currency_symbol
-
Quarters > 1 > balance Sheet > cash
1003365000
Quarters > 1 > balance Sheet > short Term Investments
1316950000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
2414122000
Quarters > 1 > balance Sheet > property Plant Equipment
14298000
Quarters > 1 > balance Sheet > total Assets
2706625000
Quarters > 1 > balance Sheet > payables
-
Quarters > 1 > balance Sheet > short Term Debt
4896000
Quarters > 1 > balance Sheet > long Term Debt
17971000
Quarters > 1 > balance Sheet > total Liabilities
100545000
Quarters > 1 > balance Sheet > equity
2656957000
Quarters > 1 > balance Sheet > currency_symbol
CNY
Quarters > 1 > cash Flow > net Income
-231846000
Quarters > 1 > cash Flow > depreciation
2808000
Quarters > 1 > cash Flow > change In Working Capital
-50409000
Quarters > 1 > cash Flow > cash From Operations
-73551000
Quarters > 1 > cash Flow > capital Expenditures
2463000
Quarters > 1 > cash Flow > cash From Investing
501562000
Quarters > 1 > cash Flow > cash From Financing
-2492000
Quarters > 1 > cash Flow > net Change In Cash
920062000
Quarters > 1 > cash Flow > currency_symbol
-
Quarters > 1 > ratios > PE
-0.15574270743959528
Quarters > 1 > ratios > PB
0.05176320422197273
Quarters > 1 > ratios > ROE
-4.283603385376579
Quarters > 1 > ratios > ROA
-4.204996998106498
Quarters > 1 > ratios > FCF
-76014000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-5.472373204708254
Quarters > 1 > health Score
34
Quarters > 2 > quarter
2024-06-30
Quarters > 2 > income Statement > revenue
22155000
Quarters > 2 > income Statement > cost Of Revenue
838245
Quarters > 2 > income Statement > gross Profit
22155000
Quarters > 2 > income Statement > operating Expenses
237754000
Quarters > 2 > income Statement > operating Income
-215599000
Quarters > 2 > income Statement > interest Expense
137210
Quarters > 2 > income Statement > pretax Income
-283238000
Quarters > 2 > income Statement > net Income
-280535000
Quarters > 2 > income Statement > eps
-0.3844456656247045
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
729713000
Quarters > 2 > income Statement > income Tax Expense
-375004
Quarters > 2 > income Statement > EBITDA
-213280000
Quarters > 2 > income Statement > operating Margin
-973.1392462198149
Quarters > 2 > income Statement > total Other Income Expense Net
-67639000
Quarters > 2 > income Statement > currency_symbol
-
Quarters > 2 > balance Sheet > cash
656256000
Quarters > 2 > balance Sheet > short Term Investments
1730517000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
2559350000
Quarters > 2 > balance Sheet > property Plant Equipment
2115000
Quarters > 2 > balance Sheet > total Assets
2896605000
Quarters > 2 > balance Sheet > payables
-
Quarters > 2 > balance Sheet > short Term Debt
1099000
Quarters > 2 > balance Sheet > long Term Debt
17817000
Quarters > 2 > balance Sheet > total Liabilities
86312000
Quarters > 2 > balance Sheet > equity
2859654000
Quarters > 2 > balance Sheet > currency_symbol
CNY
Quarters > 2 > cash Flow > net Income
-280535000
Quarters > 2 > cash Flow > depreciation
6042000
Quarters > 2 > cash Flow > change In Working Capital
-
Quarters > 2 > cash Flow > cash From Operations
-112894000
Quarters > 2 > cash Flow > capital Expenditures
765000
Quarters > 2 > cash Flow > cash From Investing
196954000
Quarters > 2 > cash Flow > cash From Financing
-2211000
Quarters > 2 > cash Flow > net Change In Cash
83303000
Quarters > 2 > cash Flow > currency_symbol
-
Quarters > 2 > ratios > PE
-0.3844456656247045
Quarters > 2 > ratios > PB
0.048023987027801265
Quarters > 2 > ratios > ROE
-9.810102900560697
Quarters > 2 > ratios > ROA
-9.6849587706988
Quarters > 2 > ratios > FCF
-113659000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-5.130173775671406
Quarters > 2 > health Score
34
Quarters > 3 > quarter
2024-03-31
Quarters > 3 > income Statement > revenue
11077500
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
11077500
Quarters > 3 > income Statement > operating Expenses
118877000
Quarters > 3 > income Statement > operating Income
-107799500
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-141619000
Quarters > 3 > income Statement > net Income
-140267500
Quarters > 3 > income Statement > eps
-0.19222283281235225
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
729713000
Quarters > 3 > income Statement > income Tax Expense
-1351500
Quarters > 3 > income Statement > EBITDA
-106640000
Quarters > 3 > income Statement > operating Margin
-973.1392462198149
Quarters > 3 > income Statement > total Other Income Expense Net
-33819500
Quarters > 3 > income Statement > currency_symbol
-
Quarters > 3 > balance Sheet > cash
656256000
Quarters > 3 > balance Sheet > short Term Investments
1730517000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
2559350000
Quarters > 3 > balance Sheet > property Plant Equipment
2115000
Quarters > 3 > balance Sheet > total Assets
2896605000
Quarters > 3 > balance Sheet > payables
-
Quarters > 3 > balance Sheet > short Term Debt
1099000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
86312000
Quarters > 3 > balance Sheet > equity
2859654000
Quarters > 3 > balance Sheet > currency_symbol
-
Quarters > 3 > cash Flow > net Income
-140267500
Quarters > 3 > cash Flow > depreciation
3021000
Quarters > 3 > cash Flow > change In Working Capital
-
Quarters > 3 > cash Flow > cash From Operations
-112894000
Quarters > 3 > cash Flow > capital Expenditures
382500
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
-2211000
Quarters > 3 > cash Flow > net Change In Cash
83303000
Quarters > 3 > cash Flow > currency_symbol
-
Quarters > 3 > ratios > PE
-0.19222283281235225
Quarters > 3 > ratios > PB
0.048023987027801265
Quarters > 3 > ratios > ROE
-4.905051450280348
Quarters > 3 > ratios > ROA
-4.8424793853494
Quarters > 3 > ratios > FCF
-113276500
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-10.225818099751748
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
49936000
Annuals > 0 > income Statement > cost Of Revenue
-
Annuals > 0 > income Statement > gross Profit
49936000
Annuals > 0 > income Statement > operating Expenses
453790000
Annuals > 0 > income Statement > operating Income
-403854000
Annuals > 0 > income Statement > interest Expense
2366000
Annuals > 0 > income Statement > pretax Income
-512381000
Annuals > 0 > income Statement > net Income
-508162000
Annuals > 0 > income Statement > eps
-0.6958778274718382
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
730246000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-401609000
Annuals > 0 > income Statement > operating Margin
-808.7431912848447
Annuals > 0 > income Statement > total Other Income Expense Net
-108527000
Annuals > 0 > income Statement > currency_symbol
CNY
Annuals > 0 > balance Sheet > cash
1003365000
Annuals > 0 > balance Sheet > short Term Investments
1316950000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
2414122000
Annuals > 0 > balance Sheet > property Plant Equipment
14298000
Annuals > 0 > balance Sheet > total Assets
2706625000
Annuals > 0 > balance Sheet > payables
-
Annuals > 0 > balance Sheet > short Term Debt
4896000
Annuals > 0 > balance Sheet > long Term Debt
17971000
Annuals > 0 > balance Sheet > total Liabilities
100545000
Annuals > 0 > balance Sheet > equity
2656957000
Annuals > 0 > balance Sheet > currency_symbol
CNY
Annuals > 0 > cash Flow > net Income
-512381000
Annuals > 0 > cash Flow > depreciation
8850000
Annuals > 0 > cash Flow > change In Working Capital
-50409000
Annuals > 0 > cash Flow > cash From Operations
-372890000
Annuals > 0 > cash Flow > capital Expenditures
3228000
Annuals > 0 > cash Flow > cash From Investing
895470000
Annuals > 0 > cash Flow > cash From Financing
-9406000
Annuals > 0 > cash Flow > net Change In Cash
513715000
Annuals > 0 > cash Flow > currency_symbol
CNY
Annuals > 0 > ratios > PE
-0.6958778274718382
Annuals > 0 > ratios > PB
0.05172545028015132
Annuals > 0 > ratios > ROE
-19.125714115809927
Annuals > 0 > ratios > ROA
-18.774747148201172
Annuals > 0 > ratios > FCF
-376118000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-7.532000961230374
Annuals > 0 > health Score
33
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
617000
Annuals > 1 > income Statement > cost Of Revenue
-55274000
Annuals > 1 > income Statement > gross Profit
617000
Annuals > 1 > income Statement > operating Expenses
545349000
Annuals > 1 > income Statement > operating Income
-544301000
Annuals > 1 > income Statement > interest Expense
494000
Annuals > 1 > income Statement > pretax Income
-184370000
Annuals > 1 > income Statement > net Income
-174829000
Annuals > 1 > income Statement > eps
-0.24011674220574097
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
728100000
Annuals > 1 > income Statement > income Tax Expense
-1344219
Annuals > 1 > income Statement > EBITDA
-168202000
Annuals > 1 > income Statement > operating Margin
-88217.34197730955
Annuals > 1 > income Statement > total Other Income Expense Net
359931000
Annuals > 1 > income Statement > currency_symbol
CNY
Annuals > 1 > balance Sheet > cash
489650000
Annuals > 1 > balance Sheet > short Term Investments
2171011000
Annuals > 1 > balance Sheet > receivables
17483000
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
2782778000
Annuals > 1 > balance Sheet > property Plant Equipment
5609000
Annuals > 1 > balance Sheet > total Assets
3198251000
Annuals > 1 > balance Sheet > payables
-
Annuals > 1 > balance Sheet > short Term Debt
3156000
Annuals > 1 > balance Sheet > long Term Debt
0
Annuals > 1 > balance Sheet > total Liabilities
125869000
Annuals > 1 > balance Sheet > equity
3119040000
Annuals > 1 > balance Sheet > currency_symbol
CNY
Annuals > 1 > cash Flow > net Income
-184370000
Annuals > 1 > cash Flow > depreciation
15674000
Annuals > 1 > cash Flow > change In Working Capital
-120733000
Annuals > 1 > cash Flow > cash From Operations
-594014000
Annuals > 1 > cash Flow > capital Expenditures
49608000
Annuals > 1 > cash Flow > cash From Investing
-104350000
Annuals > 1 > cash Flow > cash From Financing
-10977000
Annuals > 1 > cash Flow > net Change In Cash
-700922000
Annuals > 1 > cash Flow > currency_symbol
CNY
Annuals > 1 > ratios > PE
-0.24011674220574097
Annuals > 1 > ratios > PB
0.04393288319482918
Annuals > 1 > ratios > ROE
-5.6052182722889095
Annuals > 1 > ratios > ROA
-5.466393975957484
Annuals > 1 > ratios > FCF
-643622000
Annuals > 1 > ratios > Piotroski FScore
1
Annuals > 1 > ratios > fcf Percent
-1043.1474878444085
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
51626000
Annuals > 2 > income Statement > cost Of Revenue
-
Annuals > 2 > income Statement > gross Profit
51626000
Annuals > 2 > income Statement > operating Expenses
565814000
Annuals > 2 > income Statement > operating Income
-513845000
Annuals > 2 > income Statement > interest Expense
851000
Annuals > 2 > income Statement > pretax Income
-489781000
Annuals > 2 > income Statement > net Income
-484312000
Annuals > 2 > income Statement > eps
-0.6694218759934649
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
723478000
Annuals > 2 > income Statement > income Tax Expense
-37155000
Annuals > 2 > income Statement > EBITDA
-503584000
Annuals > 2 > income Statement > operating Margin
-995.3221245109054
Annuals > 2 > income Statement > total Other Income Expense Net
24064000
Annuals > 2 > income Statement > currency_symbol
CNY
Annuals > 2 > balance Sheet > cash
1190572000
Annuals > 2 > balance Sheet > short Term Investments
1806812000
Annuals > 2 > balance Sheet > receivables
11550000
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
3076899000
Annuals > 2 > balance Sheet > property Plant Equipment
19522000
Annuals > 2 > balance Sheet > total Assets
3391849000
Annuals > 2 > balance Sheet > payables
-
Annuals > 2 > balance Sheet > short Term Debt
9500000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
234352000
Annuals > 2 > balance Sheet > equity
3194614000
Annuals > 2 > balance Sheet > currency_symbol
CNY
Annuals > 2 > cash Flow > net Income
-489781000
Annuals > 2 > cash Flow > depreciation
17032000
Annuals > 2 > cash Flow > change In Working Capital
-76994000
Annuals > 2 > cash Flow > cash From Operations
-496279000
Annuals > 2 > cash Flow > capital Expenditures
139292000
Annuals > 2 > cash Flow > cash From Investing
-1433168000
Annuals > 2 > cash Flow > cash From Financing
-3042000
Annuals > 2 > cash Flow > net Change In Cash
-1664521000
Annuals > 2 > cash Flow > currency_symbol
CNY
Annuals > 2 > ratios > PE
-0.6694218759934649
Annuals > 2 > ratios > PB
0.04262128682839304
Annuals > 2 > ratios > ROE
-15.160266623761117
Annuals > 2 > ratios > ROA
-14.2787016756937
Annuals > 2 > ratios > FCF
-635571000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-12.311064192461163
Annuals > 2 > health Score
34
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
92542000
Annuals > 3 > income Statement > cost Of Revenue
-
Annuals > 3 > income Statement > gross Profit
92542000
Annuals > 3 > income Statement > operating Expenses
703019000
Annuals > 3 > income Statement > operating Income
-610477000
Annuals > 3 > income Statement > interest Expense
1175000
Annuals > 3 > income Statement > pretax Income
-4191084000
Annuals > 3 > income Statement > net Income
-4120229000
Annuals > 3 > income Statement > eps
-9.384482754693689
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
439047000
Annuals > 3 > income Statement > income Tax Expense
-70855000
Annuals > 3 > income Statement > EBITDA
-602799000
Annuals > 3 > income Statement > operating Margin
-659.675606751529
Annuals > 3 > income Statement > total Other Income Expense Net
-3580607000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
2855093000
Annuals > 3 > balance Sheet > short Term Investments
499647000
Annuals > 3 > balance Sheet > receivables
5980000
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
3413941000
Annuals > 3 > balance Sheet > property Plant Equipment
33435000
Annuals > 3 > balance Sheet > total Assets
3611699000
Annuals > 3 > balance Sheet > payables
-
Annuals > 3 > balance Sheet > short Term Debt
8969000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
300443000
Annuals > 3 > balance Sheet > equity
3342904000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-4191084000
Annuals > 3 > cash Flow > depreciation
17262000
Annuals > 3 > cash Flow > change In Working Capital
-333742000
Annuals > 3 > cash Flow > cash From Operations
-879457000
Annuals > 3 > cash Flow > capital Expenditures
1029000
Annuals > 3 > cash Flow > cash From Investing
-475756000
Annuals > 3 > cash Flow > cash From Financing
3230134000
Annuals > 3 > cash Flow > net Change In Cash
1820128000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-9.384482754693689
Annuals > 3 > ratios > PB
0.02471762437688908
Annuals > 3 > ratios > ROE
-123.25298602652066
Annuals > 3 > ratios > ROA
-114.08007699423457
Annuals > 3 > ratios > FCF
-880486000
Annuals > 3 > ratios > Piotroski FScore
1
Annuals > 3 > ratios > fcf Percent
-9.514447494110781
Annuals > 3 > health Score
34
Valuation > metrics > PE
-0.10231952921144576
Valuation > metrics > PB
0.05478755129826866
Valuation > final Score
70
Valuation > verdict
94.5% Undervalued
Profitability > metrics > ROE
-2.9786591155615207
Profitability > metrics > ROA
-3.5436834184708936
Profitability > metrics > Net Margin
-149.11077542799597
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.020710418658246507
Risk > metrics > Interest Coverage
-7.176327656858102
Risk > final Score
31
Risk > verdict
High
Liquidity > metrics > Current Ratio
461.89873977448593
Liquidity > metrics > Quick Ratio
461.89873977448593
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
42
Prev Risks > 1
-6225
Prev Risks > 2
48
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T21:31:27.264Z
Earnings History > 0 > period
2025-12-31
Earnings History > 0 > report Date
2026-03-19
Earnings History > 0 > date
2025-12-31
Earnings History > 0 > before After Market
BeforeMarket
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-
Earnings History > 0 > eps Estimate
-
Earnings History > 0 > eps Difference
0
Earnings History > 0 > surprise Percent
-
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ADo you think this GPT-powered stock app can bring you an early retirement? PCWorld
Read more →5 tech stocks that could bring gains to your portfolio in the new year Yahoo Finance
Read more →Showing 2 of 10
(Last Updated 2025-06-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Brii Biosciences Limited
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
2025-12-31
EPS Estimate
—
Date
—
EPS Actual
—
EPS Estimate
—
EPS Difference
—
Surprise Percent
undefined%
(Last Updated 2025-06-30)
(Last Updated 2025-06-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-06-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-06-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.